PI3K inhibition in preclinical models of HNSCC

被引：0
|
作者：
Hedberg, Matthew Louis [1 ]
Li, Hua [1 ]
Zeng, Yan [1 ]
Grandis, Jennifer Rubin [1 ]
机构：
[1] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2015年 / 14卷 / 07期
关键词：
D O I：
10.1158/1538-8514.PI3K14-A39
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A39
引用
收藏
页数：2
相关论文
共 50 条
  • [1] β1 integrin mediates unresponsiveness to PI3Kα inhibition for radiochemosensitization of 3D HNSCC models
    Korovina, Irina
    Elser, Marc
    Borodins, Olegs
    Seifert, Michael
    Willers, Henning
    Cordes, Nils
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 171
  • [2] Short-term PI3K Inhibition Prevents Breast Cancer in Preclinical Models
    Ku, Amy T.
    Young, Adelaide I. J.
    Ibrahim, Ahmed Atef
    Bu, Wen
    Jiang, Weiyu
    Lin, Meng
    Williams, Laterrica C.
    McCue, Bryant Lee
    Miles, George
    Nagi, Chandandeep
    Behbod, Fariba
    Li, Yi
    CANCER PREVENTION RESEARCH, 2023, 16 (02) : 65 - 73
  • [3] Short-term PI3K inhibition prevents breast cancer in preclinical models
    Ku, Amy T.
    Young, Adelaide
    Ibrahim, Ahmed A.
    Bu, Wen
    Jiang, Weiyu
    Lin, Meng
    Williams, Laterrica C.
    McCue, Bryant
    Miles, George
    Nagi, Chandandeep
    Behbod, Fariba
    Li, Yi
    CANCER PREVENTION RESEARCH, 2023, 16 (01)
  • [4] Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis
    Anna Nagel
    Julianne Huegel
    Alejandra Petrilli
    Rosa Rosario
    Berta Victoria
    Haley M Hardin
    Cristina Fernandez-Valle
    Oncogene, 2024, 43 : 921 - 930
  • [5] Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis
    Nagel, Anna
    Huegel, Julianne
    Petrilli, Alejandra
    Rosario, Rosa
    Victoria, Berta
    Hardin, Haley M.
    Fernandez-Valle, Cristina
    ONCOGENE, 2024, 43 (13) : 921 - 930
  • [6] Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer
    Ciuffreda, L.
    Del Curatolo, A.
    Falcone, I.
    Conciatori, F.
    Bazzichetto, C.
    Cognetti, F.
    Corbo, V.
    Scarpa, A.
    Milella, M.
    ANNALS OF ONCOLOGY, 2017, 28 (11) : 2896 - 2898
  • [7] Inhibition of PI3K Alpha and PI3K Delta with Copanlisib Shows Preclinical Activity As a Single Agent and in Combination in Multiple Myeloma
    Larson, Sarah M.
    Peng, Mao Yu
    Mead, Monica
    Vandross, Andrae
    Conklin, Dylan
    Von Euw, Erika
    Slamon, Dennis J.
    BLOOD, 2017, 130
  • [8] Preclinical analysis of combined PI3K and MEK inhibition as a strategy for the treatment of cancer
    Friedman, Lori
    Chan, Jocelyn
    Wallin, Jeffrey
    Edgar, Kyle
    Berry, Leanne
    Belvin, Marcia
    Hoeflich, Klaus
    CANCER RESEARCH, 2009, 69
  • [9] HER3 inhibition potentiates anti-tumor effects of PI3K inhibitors in pre-clinical models of HNSCC
    Davis, Kara S.
    Khan, Nayel
    Kemp, Carolyn
    Kulkarni, Sucheta
    Alvarado, Diego
    LaVallee, Theresa
    Grandis, Jennifer R.
    Duvvuri, Umamaheswar
    CANCER RESEARCH, 2015, 75
  • [10] Combined inhibition of MAPK and PI3K signaling augments standard chemotherapy response in preclinical models of pancreatic cancer
    Awasthi, Niranjan
    Monahan, Sheena
    Stefaniak, Alexis
    Schwarz, Margaret A.
    Schwarz, Roderich E.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
12345